Notice of Results

RNS Number : 9295D

Tissue Regenix Group PLC

03 May 2013

 

Tissue Regenix Group plc

Notice of Preliminary Results

YORK, 3 May, 2013 - Tissue Regenix Group plc ('AIM:TRX'), the regenerative medical device company, announces that it will publish its unaudited preliminary results for the year ended 31 January, 2013, on Monday 13 May, 2013.

Foradditional information please contact :

Tissue Regenix Group plc:                                          01904 435 176

Antony Odell, Managing Director

Ian Jefferson, Chief Financial Officer

Jefferies International Ltd:                                          020 7029 8000

Simon Hardy                            

Harry Nicholas

Newgate Communications                                           020 7680 6550

Alistair Kellie

Andrew Jones

About Tissue Regenix

Tissue Regenix (AIM: TRX) is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the world.

 

END

 

 

NORDMGGKNZFGFZM